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Abstract: Sarcopenia is the loss of skeletal muscle mass and function with aging. Although 
the term sarcopenia was first coined in 1989, its etiology is still poorly understood. Moreover, 
a consensus for defining sarcopenia continues to elude us. Sarcopenic changes in the muscle 
include losses in muscle fiber quantity and quality, alpha-motor neurons, protein synthesis 
rates, and anabolic and sex hormone production. Other factors include basal metabolic rate, 
increased protein dietary requirements, and chronic inflammation secondary to age-related 
changes in cytokines and oxidative stress. These changes lead to decreased overall physical 
functioning, increased frailty, falls risk, and ultimately the loss of independent living. Because 
the intertwining relationships of these factors are complex, effective treatment options are still 
under investigation. The published data on sarcopenia are vast, and this review is not intended 
to be exhaustive. The aim of this review is to provide an update on the current knowledge of the 
definition, etiology, consequences, and current clinical trials that may help address this pressing 
public health problem for our aging populations.
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Introduction
The term sarcopenia first coined by Irwin Rosenberg1 in 1989 is now widely accepted 
to describe the steady and involuntary loss of skeletal muscle mass during aging. 
Although the word sarcopenia is used in the field of gerontology to describe this 
phenomenon of aging, the complex multifactorial changes in muscle fiber quantity 
and quality, protein synthesis rates, alpha-motor neurons of spinal cord, anabolic and 
sex hormone production are poorly understood. These changes combine and result 
in a smaller, slower contracting muscle with impaired capacity to generate sufficient 
strength and power for activities of daily living.2 In concert with these multifactorial 
changes are decreased basal metabolic rate, increased dietary protein needs, and 
increased exposure to oxidative stress and inflammation.3,4 The sum of these changes 
leads to decreased overall physical functioning and physical activity, increased frailty, 
falls risk, and fractures, and ultimately to the loss of independent living. The burden 
of these changes and outcomes related to sarcopenia occurs at both the individual and 
the societal levels. In 2004, Janssen et al5 estimated that the annual healthcare cost 
attributable to sarcopenia was approximately $18 billion in the United States. In the 
current environment of global aging, the future health burden of sarcopenia is self-
evident, and interventions are needed to slow or reverse the loss of muscle mass and 
function in our aging populations.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Challenges to these efforts exist because there is no 
consensus on an operational definition of sarcopenia, and 
the development and progression of sarcopenia is a   complex 
process that will require multifaceted approaches. This 
review summarizes the recent literature on nutrition, physical 
  activity, and therapeutic interventions to prevent or ameliorate 
sarcopenia. It begins with an overview of how sarcopenia is 
measured and defined.
Defining sarcopenia
More precise methods for measuring skeletal muscle mass 
include dual-energy x-ray absorptiometry (DXA), magnetic 
resonance imaging, and computed tomography although 
new technologies such as positron emission tomography 
and functional magnetic resonance imaging may extend the 
capability of estimating both “mass” and   corresponding “func-
tion.”6 However, these measures are costly and not always 
available outside clinical settings. Bioelectrical impedance 
analysis (BIA) and anthropometry have also been used, but 
limitations due to hydration status with BIA and the risk of 
random and systematic errors while collecting anthropometric 
measures make these methods less than ideal. Moreover, 
these methods collect superficial measures such as electrical 
resistance, skinfold thicknesses, or   circumferences that can 
be used only to indirectly index or predict muscle mass.7 
Baumgartner et al8 were the first to develop an operational 
definition of sarcopenia. The approach used sex-specific cutoff 
values on the statistical distribution of “relative skeletal muscle 
mass,” which was defined as appendicular skeletal muscle 
mass (ASM) (sum of the masses of arm and leg lean soft tis-
sues from DXA) divided by height squared (also referred to 
as stature, ASM/S2). The cutoff values for the ASM/S2 index 
were defined as −2 standard deviations below the sex-specific 
means of the distributions in a reference sample of young and 
middle-aged adults from the Rosetta Study.9 Cutoff values 
of less than 5.45 kg/m2 for women and 7.26 kg/m2 for men 
were applied and shown to identify elders in the New Mexico 
Aging Process Study who were at increased risk for balance 
and gait problems, and other correlates of muscle function. 
The estimated prevalence of sarcopenia in the New Mexico 
Elder Health Survey increased from 13% to 24% in people 
younger than 70 years to .50% in people older than 80 years of 
age, and was slightly greater in Hispanics than in non-Hispanic 
whites.8 Some subsequent surveys of sarcopenia prevalence in 
different populations have used these cut scores and arrived at 
different estimates; however, most of the surveys used different 
definitions or study populations with different age, racial, and 
gender   characteristics. For example, Melton et al10 proposed 
cut scores of 6.0 kg/m2 in women and 8.7 kg/m2 in men for a 
sarcopenia index defined as total lean body mass/stature2. They 
derived lower prevalence estimates but their population included 
people younger than 50 years. Other recent data from Asian 
countries suggest that higher cut scores are more appropriate 
for this population.11–13 Janssen et al14 used receiver operat-
ing characteristic curve analysis to estimate optimal cutoff 
values for predicting disability in a representative US sample 
(NHANES III) using total skeletal muscle mass (TSM, from 
BIA) adjusted for stature (TSM/S2). Cut-off values in the Jans-
sen study for women ranged from 5.76 to 6.75 kg/m2 and were 
associated with moderate levels of disability.  Less than 5.75 kg/
m2 was associated with high physical disability risk. In men the 
cut-off values ranged from 8.51 to 10.75 kg/m2. Interestingly, if 
these cutoff values are adjusted to approximate ones based on 
ASM, rather than total muscle mass, they are similar to those 
originally derived by Baumgartner et al.8 Subsequently other 
investigators have explored a variety of measures including 
calf muscle circumference, muscle mass as a percent of body 
weight, the ratio of total lean soft tissue mass to total fat mass, 
or residuals from a linear regression model.15–17 These estimates 
suggest the original cut scores put forth by Baumgartner 
from an older New Mexican population may overestimate 
the prevalence of sarcopenia in some populations and that 
higher cut scores may be appropriate. In fact, Baumgartner 
and coworkers18 recognized that their initial estimates were too 
high in a subsequent analysis. To date, no consensus has been 
reached as to the “best” definition of sarcopenia. Some, in fact, 
have suggested that the “best” measure should be based on 
muscle strength rather than on mass particularly in the context 
of cardiovascular disease risk.19
The prevalence of sarcopenia
Based on the above discussion, it is apparent that the     preva-
lence of sarcopenia in specific populations will vary depend-
ing on the methods used to assess muscle mass and the cut 
scores applied. The prevalence of sarcopenia in the United 
States and parts of Europe has been reported to be 5%–13% 
in people aged 60–70 years and 11%–50% in those older than 
80 years.17,20–22 Sex-specific data in the US data reports that23 
53% males and 43% females older than the age of 80 were 
sarcopenic.23 Data from Asian countries report the prevalence 
of sarcopenia to be between 8% and 22% for females and 
between 6% and 23% for males.11,12 Until a consensus is 
reached on the standard method to measure skeletal muscle 
mass and population-specific cut scores, the prevalence of 
sarcopenia will vary widely across different populations. 
Nonetheless, a common feature in all studies to date is the Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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increasing prevalence of sarcopenia with increasing age. On a 
global level, increasing longevity combined with low fertility 
and immigration poses the question whether sarcopenia and 
its sequel of functional limitations will emerge as a significant 
public health concern. Moreover, what prevention measures 
are most effective in slowing or reversing the loss of muscle 
in later life?
Rate of muscle loss
It has been established that muscle loss is a significant 
feature of aging. The rate of muscle loss is estimated to 
be 1%–2% annually after the age of 5024,25 in concert with 
strength declines of 1.5% per year that accelerates to 3% 
annually after the age of 60.18,26,27 These losses result in 
a decrease in total muscle cross-sectional area of about 
40% between 20 and 60 years of age,27 and are even higher 
in sedentary individuals and twice high in men compared 
with women.26,28 Two longitudinal studies investigating 
age-related, sex-specific losses of skeletal muscle mass 
reported losses in both sexes, but the loss of fat-free mass 
occurred at a faster rate in men even after adjusting for free 
testosterone, insulin-like growth factor-1 (IGF-1), physical 
activity, and serum albumin.29,30 Grip strength also declines 
with age and has been reported as a predictor of physical 
functioning and disability.31,32 Data from 3 large nationwide 
population-based surveys in Denmark (8,342 participants, 
aged 45–102 years, with up to 4 year follow-up) reported 
that grip strength declines almost linearly between 50 and 
85 years of age. However, among the oldest women, the 
longitudinal curve reached a horizontal plateau.33 Lower 
health-related quality of life has also been reported in older 
men and women with lower grip strength and could not be 
explained by age, size, physical activity, or comorbidity. The 
investigators proposed that this reflected the link between 
sarcopenia and generalized frailty.34
Accompanying the age-related loss of muscle mass is 
the increase of fat mass. It is reported that an average adult 
can expect to gain approximately 0.45 kg (1 lb) of fat and 
lose about 0.23 kg (0.5 lb) of muscle yearly between 30 and 
60 years of age.35 This shift in body composition is often 
masked by stable body weight and can result in a body 
composition phenotype known as sarcopenic obesity.24,28 It is 
more difficult to detect a sarcopenic-obese person as clinical 
measures of body mass index (BMI) and weight are not sensi-
tive to these shifts in body composition. It is estimated that 
approximately 30% of men and 10% of women older than 
80 years have sarcopenic obesity.18,20,26 This might explain 
the discrepancy between Zamboni et al30 who reported 
significant increases in total body fat (1.31%) and percent 
body fat (1.27%) in women but not in men over 2 years (age 
range 68–78 years at baseline) and Dey et al29 who reported 
that percent body fat increased only in men (P , 0.05) after 
examining a slightly smaller and older (75–80 years) cohort 
with a 5-year follow up. This would suggest that there is 
an interaction between age and sex for body composition 
changes. More important than the existence of these body 
composition phenotypes is perhaps their relationship with 
health and physical function.
Correlates of sarcopenia
Poor outcomes such as loss of strength, mobility disorders, 
disability, and poor quality of life have been associated with 
sarcopenia.36–43 Although sarcopenia is the focus of this review, 
a U-shaped relationship between BMI and functional limita-
tion and disability has been reported. Older adults with BMIs 
,18, who have low muscle and fat mass, have an increased 
prevalence of function and mobility limitation and disability. 
Conversely, older obese people with BMIs .30 also have 
an increased prevalence of functional limitation and disabil-
ity.20,39 The sarcopenic-obese body composition phenotype 
described above, which cannot be detected by BMI, has also 
been associated with poorer physical functioning, disability, 
falls,22,44,46–49 and metabolic syndrome.48 Some studies suggest 
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that sarcopenic obesity may be better for predicting functional 
consequences than for predicting the loss of skeletal muscle 
mass alone (pure sarcopenia).40,45,46–49   Conversely,   others 
argue that it is the combination of low muscle strength with 
obesity that is associated with poorer physical function.50,52 
Still others report that pure obesity is the greater risk factor 
for functional deficits.53–55 Although it is important to address 
these conflicting data, and as these   questions are the subject of 
ongoing investigations, it is beyond the scope of this review 
to address these differing views.
Metabolic rate and maximal oxygen consumption 
(Vo2 max) also decrease with the loss of muscle mass,25,56,57 
and this could create higher perceived energy expenditure at 
lower levels of work output as was reported by Waters et al58 
in physically trained sarcopenic adults. The sarcopenic group 
performed significantly less total work during the resistance 
exercise and used more energy for less work when compared 
with nonsarcopenic people matched for self-reported physical 
activity. If the total work output decreases with sarcopenia, and 
there is a preferential loss of type 2 muscle fibers and motor 
neurons, it may result in slower twitch contraction time and 
maximal shortening speed causing the loss of both muscular 
strength and power.6 Leg power has been associated with func-
tional limitations and is reported to have separate attributes 
that could influence physical performance.59,60 The combined 
effects of Vo2 max and decreasing   muscular strength and power 
most likely contribute to the loss of   function during aging. 
There may also be sex-specific   differences as older males 
apparently rely more on strength and women on coordination 
when performing the same physical task.61 Finally, skeletal 
muscle is also an important reserve of body protein during the 
times of malnutrition or stress.62 If sarcopenia is particularly 
severe, it will have the potential not only to reduce resting 
metabolic rate but also to negatively influence the immune 
system, thereby reducing the body’s ability to respond to 
homeostatic challenges and create a vicious downward spiral 
of muscle loss, sarcopenia, frailty, and disability.63–65
Muscle protein balance  
and nutritional intake
In healthy muscle, proteins and amino acids constantly 
turn over in equilibrium between protein synthesis and 
breakdown.66,67 This equilibrium is typically disrupted in 
older people with up to a 30% lower synthesis rate of mixed 
muscle proteins including myofibrillar and mitochondrial 
proteins.67–69 It is also been hypothesized that sarcopenia 
may result from increased rates of protein breakdown under 
the stimulation of chronic inflammation,64 but this is less 
well established. The evidence in support of this alternative 
hypothesis will only be briefly discussed.
Muscle protein synthesis is stimulated by dietary intake of 
both essential and nonessential amino acids, such as leucine 
and creatine,70–72 but it remains unclear how significant 
decreases in dietary and protein intake influence the devel-
opment and progression of sarcopenia. Overall, low nutrient 
intake secondary to the “anorexia of aging” is considered an 
important risk factor in the development and progression of 
sarcopenia.18,69,73,74 It is also reported that 15% of those older 
than 60 years eat less than 75% of the recommended daily 
allowance for protein.75 Morley69 reviewed the phenomena 
of the anorexia of aging and reported that early satiety, 
secondary to decreased relaxation of the fundus, increased 
the release of cholecystokinin in response to fat intake, and 
that increased leptin levels and neurotransmitters may all 
play a role in the anorexia of aging. Declining testosterone 
levels may account for decreasing food intake to a greater 
extent in men than in women.6,76 Thus, although poor overall 
nutritional intake may play a role in sarcopenia, low protein 
intake appears to be a significant problem for older adults and 
may be a potential target for an intervention strategy.
Nutritional interventions
Daily intake of 1.2–1.5 g/kg of protein has been reported to 
prevent sarcopenia, whereas the current recommended daily 
dietary protein intake requirement for adults is 0.8 g/kg/d.6 
Preliminary data from a recent randomized controlled trial 
indicate that it is more important to ingest a sufficient amount 
of high-quality protein (25–30 g) with each meal rather than 
1 large bolus, because greater than 30 g in a single meal may 
not further stimulate muscle protein synthesis.77 Furthermore, 
Paddon-Jones and Rasmussen78 reported that aging does not 
inevitably reduce the anabolic response to a high-quality 
protein meal, rather it is the   presence of carbohydrates that 
blunts this response due to the effects of insulin resistance on 
muscle protein synthesis. These data would suggest that high-
quality protein should be consumed in smaller quantities, but 
not together with carbohydrates. These   recommendations may 
not be easy to achieve. Volpi et al have conducted a number 
of experiments investigating muscle protein synthesis and 
breakdown, and amino acid transport in young and elderly 
subjects. In 2003, they assessed whether nonessential amino 
acids are required in a nutritional supplement to stimulate 
muscle protein anabolism in the elderly and reported that 
essential amino acids are primarily responsible for the amino 
acid stimulation of muscle protein anabolism in healthy 
elderly adults.72Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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There is a general agreement that the essential amino acid 
leucine increases protein anabolism and decreases protein 
breakdown.78 Leucine-rich food sources include legumes 
such as soybeans and cowpea, and animal products such as 
beef and fish. Amino acid supplements without adequate 
leucine reportedly do not stimulate protein synthesis.71,79,80 
Meat-based products contain higher essential amino acids 
than vegetable-based and it was suggested by Kim et al45 
that older adults should be encouraged to consume a diet 
higher in lean meat sources or consume essential amino acid 
supplements particularly if they are engaging in resistance 
training, as discussed later in this review. The authors are 
aware of the 3 registered clinical trials currently being 
conducted to investigate protein   nutritional supplements and 
sarcopenia. These are being conducted at the University of 
Texas Galveston, Maastricht University Medical Center, and 
Centre Hospitalier   Universitaire de Nice. All are nutritional 
supplement and resistance training interventions. It is 
anticipated that these trials and possibly other trials will shed 
more light on the amount, type, and timing of nutritional 
supplements either alone or in combination with resistance 
training to reduce, stabilize, or reverse sarcopenia.
Vitamin D has recently received recognition as another 
potential intervention strategy for sarcopenia. Older adults 
are at increased risk of developing vitamin D insufficiency 
(,30 ng/mL), and a recent systematic review of vitamin D 
supplementation reports that supplementation may be indicated 
in those older people with low vitamin D levels to combat 
sarcopenia, functional decline, and falls risk.81 As people 
age, skin cannot synthesize vitamin D efficiently and the 
kidney is less able to convert vitamin D to its active hormone 
form.82 Salmon, tuna, mackerel, and other fish oils are among 
the best sources of vitamin D, with small amounts found in 
beef liver, cheese, and egg yolks. Vitamin D in these foods 
is primarily in the form of vitamin D3 (cholecalciferol) and 
its metabolite 25(OH)D3.83 People may try to meet their 
vitamin D needs through exposure to sunlight,84,85 but seasons, 
geographic latitude, time of day, cloud cover, skin melanin 
content, and sunscreen are among the factors that affect 
exposure to UV radiation and vitamin D synthesis.86–88 Thus, 
vitamin D supplements are necessary and are available in 
2 forms, D2 (ergocalciferol) and D3 (cholecalciferol). Many 
vitamin D supplements are being reformulated to contain 
vitamin D3 instead of vitamin D2
89 although both forms 
(as well as vitamin D in foods and from cutaneous synthesis) 
effectively raise serum 25(OH)D levels.85 A meta-analysis by 
Dawson-Hughes81 indicated that the evidence for vitamin D 
supplementation was strong although the dosing, efficacy, and 
long-term safety of supplementation need to be elucidated. 
Molecular mechanisms of vitamin D on muscle tissue include 
the genomic effects that result in changes in gene transcrip-
tion of messenger RNA and protein synthesis, and the rapid 
nongenomic effects mediated through the vitamin D receptor 
on muscle cells.90 Although our understanding of the relation-
ship between vitamin D and muscle function has advanced 
over the past decade, a complete understanding of the vitamin 
D action on muscle tissue and how this translates into improve-
ments in muscular performance are yet to be elucidated. Cur-
rently, there appears to be at least 2   clinical trials investigating 
vitamin D supplementation: A Pilot Study of the Impact of 
Vitamin D3 on Muscle Performance in Elderly Women at Tufts 
University, and the Zurich   Disability   Prevention Trial at the 
University of Zurich.
Physical activity
As has been discussed, the development and progression of 
sarcopenia are complex and multifactorial. Despite this, there 
is a growing body of evidence to indicate that   physical activity 
can slow the loss of skeletal muscle and function. Although 
physical inactivity aggravates the loss of skeletal muscle, 
highly active older adults continue to lose   cardiovascular 
fitness and muscle mass over time.25,56,57 This stresses the 
importance of the mode of activity in the preservation of 
lean body mass. A recent 3-year longitudinal study of body 
composition and physical activity in older adults91 reported 
that body weight remained stable while lean body mass 
decreased and fat mass increased. This confirmed the earlier 
studies reporting these shifts in body composition and that 
these changes cannot be detected by body weight or BMI.24,28 
Moreover, they found that leisure-time physical activity 
did not prevent the changes in body composition although 
higher levels of physical activity were associated with higher 
muscle mass.
Physical activity encompasses 4 domains: leisure time, 
occupational, transport, and household. For the purpose 
of this review we will only focus on leisure-time physical 
  activity and then more specifically resistance training.
Leisure-time physical activity
In the longitudinal study by Raguso et al,91 the average time 
spent in moderate to intense activities reported by the active 
participants was 90 minutes a day, with approximately 70% 
reporting over 60 minutes a day. Examples of moderate-to-
intense activities in this study were walking up stairs, running, 
biking, playing tennis, skiing, and swimming. None of the 
activity included resistance training. Although this level of Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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physical activity meets or exceeds the standards recommended 
by American Heart Association for cardiovascular exercise,92 
it was not sufficient to maintain lean mass or decrease fat 
mass. It is a bit surprising that this level of exercise did not 
positively influence body composition, but highlighted the 
issues of information bias, particularly social desirability bias, 
in self-reported physical activity. This is particularly the case 
for intensity, where people report significantly higher intensity 
mistaking low levels of exercise intensity for moderate levels 
of intensity.93 Mitchell et al94 also reported similar findings 
from a large cross-sectional study, where lean muscle mass 
was not associated with physical activity or dietary intakes.
Conversely, others have reported that high levels of physical 
activity slow the loss of skeletal muscle oxidative capacity 
and sarcopenia.95,96 These   conflicting results are likely due 
to different study designs, activities, and challenges of self-
reported physical activity. Moreover, very few studies have 
included people greater than 80 years of age in whom the 
prevalence of sarcopenia is highest. It also raises the principle 
of overload to achieve improvements in strength, power, and 
hypertrophy in response to resistance training.
Resistance training
Recent evidence on resistance training supports earlier research 
that it may be the most effective strategy to combat sarcopenia 
through muscle hypertrophy and increased muscular strength 
and power.97–99 Until recently, research has focused on the 
impact of resistance training on muscular strength rather than 
power, which is the product of force and speed. The decline in 
muscular power is much steeper than strength and results in a 
decreased ability to rapidly produce force.100,101 As discussed 
earlier, the loss of muscular power is due to the preferential 
loss of fast-twitch fibers and motor units,27,43,63,75 and has 
been associated with lower functional status and risk of fall-
ing.13,23,46,101–104 The following sections will discuss current 
research on strength and power resistance training targeted to 
older adults to combat the loss of   sarcopenia and functional 
loss. Table 1 presents the commonly used terminology in 
resistance training exercise prescription.
Strength training
There is a growing body of evidence documenting the benefits 
of strength training for older adults. A systematic review by 
Latham et al105 reported that most strength training programs 
had durations of 8–12 weeks, used 2–3 sets of 8–10 rep-
etitions at 65% of 1-repetition maximum (1 RM), and were 
performed 2–3 days per week. This type of strength train-
ing focuses on concentric or shortening muscle contraction 
and has little influence on eccentric or lengthening muscle 
strength.106,107 Most of the reviewed studies by Latham et al105 
reported increases in strength, but found limited changes in 
functional tests such as chair stands and timed up and go. 
One might assume that resistance training that results in 
improvements in strength and/or power would also improve 
physical   functioning. A recent Cochran review included 121 
trials with 6,700 participants assessing progressive resistance 
training and physical function.108 For the most part, progres-
sive resistance training was performed 2–3 times weekly at a 
high intensity. The resistance training programs had a large 
positive effect on muscle strength and a small but significant 
improvement in physical ability. There was a modest improve-
ment in gait speed and a moderate to large effect for getting out 
of a chair. These authors concluded that progressive resistance 
training is an effective intervention for improving strength 
and physical functioning in older people, including   functional 
performance of some simple and complex tasks. They cau-
tioned that adverse events were not sufficiently reported; thus, 
transferring these exercises to clinical populations should 
be approached with caution. Although this review did find a 
positive relationship between progressive resistance training 
Table 1 Terminology and definitions
Muscular strength Amount of force produced for 1 maximal effort
Muscular endurance Ability of a muscle to contract repeatedly
Muscular power Product of force and speed of movement
exercises Movements that target specific muscle groups from large muscle groups to isolated muscle movements
Repetition One complete movement of an exercise
1 repetition maximum (1 RM) Maximal weight that can be lifted for 1 repetition, safely and with proper form
Set Series of continuous repetitions (eg, 10 repetitions/set)
Intensity Amount of weight lifted specified as either a percentage of 1 RM (eg, 70 % of 1 RM) or a specified 
number of repetitions within a set
Frequency Number of days per week each exercise session is conducted
Duration Length of time for each exercise session
volume Sum of frequency, intensity, and durationClinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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with strength and function, it did not specifically address the 
question of power versus strength training.
Power training
As noted earlier and in association with the greater loss of type 
2 muscle fibers, muscular power declines at a faster rate than 
strength. There is also evidence that muscular power impacts 
more on physical functioning than strength.97,98,107,109–114 Many 
published studies of power training used 3–4 sets at intensities 
of 20%–80% of 1 RM, 2–3 times per week for 8–16 weeks. 
All of these studies reported significant improvement in 
strength and power, with some reporting improved measures 
of physical functioning.109,112,113,115 On one hand, 2 randomized 
controlled trials comparing strength to power training98,109 
reported similar improvements in strength but greater 
improvements in power performance. On the other hand, other 
trials112,114 reported similar improvements in both strength and 
power performance. These data highlight the symbiotic rela-
tionship in the physiological response to strength and power 
training, whereby the response to power training results in 
gains of both strength and power.   Conversely, strength train-
ing generally only increases strength but does not improve 
power unless the speed of contractions is very high.98
Several recent investigations have reported that physical 
function, particularly in the lower limbs, has a stronger rela-
tionship with muscular power than strength.60,102,104 In order 
for skeletal muscle to achieve and maintain muscular strength 
and power, resistance training needs to use a progressively 
increasing load to maintain the desired range of repetitions 
per set of exercise. The American College of Sports Medicine 
recently put forward a position statement on progressive 
resistance training in healthy adults.92 They recommended a 
2%–10% increase in load when the individual can perform the 
current workload for 1–2 repetitions over the desired number. 
They also recommended that progression in power training 
uses 2 loading stages: the first stage is strength training and 
the second stage is light loads (0%–60% of 1 RM for lower 
body exercises; 30%–60% of 1 RM for upper body exercises) 
performed at a fast contraction velocity with 3–5 minutes of 
rest between sets for multiple sets per exercise (3–5 sets). This 
is slightly different from intense loading used during power 
training and reported in the above studies.
Resistance training combined  
with nutritional interventions
Although the evidence for resistance training to combat 
sarcopenia is convincing, Johnston et al116 questioned 
whether this intervention effectively interferes with 
the processes underlying sarcopenia or only masks the 
effects. Adults between 65 and 75 years reportedly have 
a blunted cellular or molecular muscle hypertrophy and 
protein synthesis response to resistance training compared 
with younger people.46,117 In animal models combining 
nutritional interventions, such as high-protein or leucine 
ingestion, with resistance training, anabolic processes 
appeared enhanced and catabolic pathways were inhibited 
in older skeletal muscle.118 A eucaloric diet supplemented 
with moderately high levels of protein (30 to .100 g) also 
demonstrated enhanced muscle tissue accumulation and 
reversed the blunted protein synthesis response to resistance 
training.119,120 Alternatively, a 15-g bolus of essential amino 
acids 1 hour after moderately intense resistance training 
(70% of 1 RM) in older participants normalized protein 
synthesis to a younger pattern of protein synthesis over 
a period of 5 hours after ingestion.121   Recently ornithine 
alpha-ketoglutarate (OKG), which is a precursor of amino 
acids such as glutamine and arginine, is receiving attention 
as a potential nutritional strategy to modulate muscle protein 
metabolism during aging.122
The authors are aware of the 3 clinical trials being 
conducted across France, Belgium, and the United States to 
investigate the relationships between protein supplementation 
and resistance training on muscle protein metabolism in 
older adults.
Therapeutic interventions
In addition to nutritional and exercise interventions, other 
therapeutic modalities have also been used to prevent, delay, 
or reverse sarcopenia including anabolic hormones such 
as testosterone, estrogen, and growth hormone (GH); cre-
atine; angiotensin II converting enzyme inhibitors (ACEIs); 
and antimyostatin agents. Newer agents such as antimyostatin 
and specific androgen receptor modulators (SARMs) are in 
early stages of testing for safety and efficacy, whereas the 
older interventions (ie, testosterone and GH) have position 
statements regarding their efficacy and safety. These are 
discussed briefly below.
In males, testosterone decreases by 1% per year and 
  bioavailable testosterone by 2% per year from age 30.76,123,124 
In women, testosterone levels drop rapidly from 20 to 
45 years of age.125 Currently, testosterone replacement is 
not recommended for the treatment of sarcopenia due to 
the high rates of side effects and low benefits to physical 
  performance.126 SARMs may hold more promise for anabolic 
effects on skeletal muscle without the side effects,127 but are 
in the early stages of clinical investigations.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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The release of GH from the pituitary and subsequent 
IGF-I synthesis decreases with increasing age. This lead 
to investigations administering recombinant growth 
hormone (rGH) to older patients either with rGH alone 
or in combination with sex steroids or exercise.124,128,129 
The results of these studies did not support the use of rGH 
in older   nonhypopituitary adults as it did not show efficacy, 
had high rates of adverse events, and increased the risk of 
  neoplasia.129 A statement released by Growth Hormone 
Research Society in the United States recommended that until 
carefully designed, long-term studies using validated outcome 
parameters are conducted, the clinical use of rGH in older 
adults, alone or in combination with testosterone, cannot be 
recommended. Similarly, estrogen and tibolone (a synthetic 
steroid with estrogenic, androgenic, and   progestogenic 
properties) are not recommended until further research is con-
ducted to determine the long-term safety in older adults.130
Antioxidants
Oxidative stress has also been suggested in the etiology of 
sarcopenia and is influenced by both the increased generation 
of reactive oxygen species (ROS) and age-associated 
decreases in antioxidant defense.131 Exposure to high levels 
of ROS is reported to modify mitochondrial DNA, the 
electron transport system, and result in reduced Ca2+ uptake 
by the sarcoplasmic reticulum ultimately accelerating 
ROS production and leading to myofiber death.3,132,133 
Nonexhaustive exercise stimulates the expression of certain 
antioxidants through enzymatic pathways and it has been 
questioned whether exercise training should be supplemented 
with exogenous antioxidants.131 Recently, Fusco et al134 wrote 
a salient review on antioxidant supplementation stressing that 
a better understanding of oxidation mechanisms, markers of 
oxidative damage and antioxidant status, and timing of anti-
oxidant supplementation is needed before the widespread use 
of antioxidant supplementation can be advised or refuted.
Until such time, foods may be a preferred source of 
antioxidants because they contain a wide array of antioxidant 
substances and are also high in vitamins, minerals and fiber. 
Vegetables rich in antioxidants include pinto, red and black 
beans, and russet potatoes. Fruits include berries such as 
cranberry, blueberry, blackberry, and raspberry, and also 
plums, apples, cherries, prunes and pecans.135
Creatine
Dietary creatine is derived primarily from meat (1 kg 
contains ∼5 g of creatine) and is nonenzymatically converted 
to creatinine. Creatine monohydrate was considered a 
potential ergogenic aid due to its buffering action against 
proton accumulation and by the increasing skeletal muscle 
concentrations of phosphocreatine needed for high-intensity 
muscular contractions.136 Creatine supplementation combined 
with resistance training has been reported to be effective for 
increasing strength in older adults.137–139 Creatine appears well 
tolerated in these short-term studies, but there are few data 
on long-term studies. Because the mechanisms of creatine 
actions are poorly understood, more long-term trials are 
needed to determine its safety and efficacy for renal, hepatic, 
cardiac, and muscle functions.
Angiotensin II converting enzyme 
inhibitors (ACeIs)
ACEIs works by suppressing the angiotensin – aldosterone 
system, thereby preventing the formation of angiotensin II 
that acts as a powerful vasoconstrictor.140 Blood pressure is 
partially regulated by ACEIs. It also reduces the pre- and 
afterload on the heart improving myocardial contractility.141 
ACEIs are widely used in treating hypertension and heart 
failure in older adults,142 and 3 cohort studies have reported 
improved body composition and physical function associ-
ated with ACEIs in older adults.143–145 A recently completed 
randomized controlled trial of ACEIs reported improve-
ments in exercise capacity and fewer falls in 130 older 
participants with existing impairments of activites of daily 
living (ADLs).146 The mechanisms of ACEIs are unclear but 
have been suggested to involve improved cardiac output and 
thus improved blood flow to muscle, reduce inflammatory 
cytokines, improve endothelial function and muscle glucose 
uptake, and positively modulate the IGF-1 system, all of 
which have implications for body composition changes.147 
Because ACEIs have been prescribed since the 1980s to treat 
hypertension and heart failure in older adults, the long-term 
safety of ACEIs may already be established. Thus, although 
the mechanisms for ACEI action on skeletal muscle are yet 
to be elucidated, it could be a safe and effective means to 
improve body composition and function in older adults.
Myostatin
Myostatin is a member of the transforming growth   factor-beta 
superfamily and is known to be a negative regulator of skel-
etal muscle myogenesis.148,149 The primary action of myostatin 
is the negative regulation of skeletal muscle   satellite cell 
  activation, proliferation, and cell self-renewal.150 Currently, 
clinical trials of antimyostatin drugs are confined to animal 
models and it will be some time before trials are conducted 
in humans.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Conclusion
Although the functional and financial consequences of 
sarcopenia are significant from a public health perspective, 
clinical cut scores for specific populations are needed before 
sarcopenia can be diagnosed and treated. With exception of 
ACEI as a pharmaceutical intervention, the most compel-
ling evidence to combat sarcopenia is resistance training 
either alone or in combination with nutritional supplements. 
  Considering the multifactorial nature of the sarcopenic pro-
cess, comprehensive interventions such as those mentioned 
above are likely needed. Certainly, the cornerstone inter-
ventions of resistance training and nutritional supplements 
should be considered and adopted when possible. The feasi-
bility, sustainability, and safety of power resistance training in 
older adults and the influence of nutritional supplementation 
with power training need to be confirmed by larger longitudi-
nal trials. There are also issues regarding how to implement 
resistance-training programs into the community- or home-
based programs. Community-based programs are gaining 
popularity, and the feasibility of peer-led strength classes has 
been reported.151 Home-based programs may be an option for 
frail elderly who are home bound.152,153 Finally, pharmaco-
logic approaches under investigation also hold promise for 
a greater understanding of the mechanisms and potential 
interventions to combat or reverse sarcopenia.
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